Oslo, May 18, 2022: The Board of Arxx Therapeutics AS, a biotechnology company pioneering the development of novel therapeutics for fibrotic disease, today announced the appointment of Øystein Soug as CEO, effective today. Øystein Soug comes from Targovax ASA, an Oslo Stock Exchange listed biotechnology company, where he has served as CEO of Targovax since […]